Information provision for antibacterial dosing in the obese patient: a sizeable absence?

BACKGROUND: Obesity is on course to overtake being underweight as a global disease burden. Obesity alters antibacterial pharmacokinetics (PK) and pharmacodynamics (PD). Historically, drug PK/PD parameters have not been studied in obese populations. This means dose recommendations risk being sub-ther...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Antimicrob Chemother
Egile Nagusiak: Boyd, Sara Elizabeth, Charani, Esmita, Lyons, Tracy, Frost, Gary, Holmes, Alison Helen
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2016
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5890658/
https://ncbi.nlm.nih.gov/pubmed/27538956
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkw324
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak